



05-30-01

0590
Docket No: AHP 98126-C1
Patent

#3

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ozenberger, *et al.*

Serial No.: 09/774,936 Group Art No.: Not Yet Assigned

Filed: January 31, 2001 Examiner: Not Yet Assigned

For: β -Amyloid Peptide Binding Proteins and Polynucleotides
Encoding Same

Confirmation No.:

Customer Number: 25291

Commissioner for Patents
Box DD
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL564582276US addressed to the Commissioner for Patents, Box DD, Washington, DC 20231.

May 29, 2001
Date

Julia Richie
Julia Richie

2. Identification of Time of Filing

This Information Disclosure Statement

- a. is filed within three months of the filing date of the application.
- b. is filed before the mailing date of a first Office Action on the merits.
- c. is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. Certification under 37 CFR 1.97(e)

The undersigned attorney certifies

- a. that items of information contained in the Information Disclosure Statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

4. Newly Cited Information

A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed. **Copies of the International Search Reports dated November 11, 1998, and April 27, 2000, are also enclosed.**

5. No copy of the patents, publications or other information previously cited is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Items AR-AS5 were previously cited in prior application Serial Number 09/060,609, filed on April 15, 1998, or Serial Number 09/172,990, filed on October 14, 1998.

6. Concise Explanation
Documents cited above which are not in the English Language
a. have been explained in the specification.
b. have an abstract (or other concise explanation) in English enclosed or if
readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

Fees
 Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:

Charge Deposit Account No. 01-1425 in the amount of \$0.00
A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:


Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.



Gavin T. Bogle

Attorney for Applicants
See attached certificate

American Home Products Corporation
Patent Law Department
Five Giralta Farms
Madison, NJ 07940-0874
Tel. No. (617) 665-8079

LIST OF PATENT AND PUBLICATION FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (USE SEVERAL SHEETS IF NECESSARY) 	Docket No.: AHP-98126-C1		Application No.: 09/774,936	
	Applicant(s): B.A. Ozemb rger et al.			
	Filing Date: January 31, 2001		Group Art Unit:	

US PATENT DOCUMENTS

Examiner Initial		Doc. No.	Date	Name	Class	Sub-Class	Filing Dat
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Doc. No.	Date	Country	Class	Sub-Class	Translation Yes No
	AL	WO 96/25435	22 Aug 96	PCT			
	AM	WO 88/03951	2 Jun 88	PCT			
	AN	WO 96/13513	9 May 96	PCT			
	AO	WO 98/46636	22 Oct 98	PCT			
	AP	WO 99/46289	16 Sep 99	PCT			
	AQ	WO 99/24836	20 May 99	PCT			
	AL2	WO 00/22125	20 Apr 00	PCT			

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

1.	AR	J. Biol. Chem., "Modulation of GDP Release from Transducin by the Conserved Glu ¹³⁴ Arg ¹³⁵ Sequence in Rhodopsin", S. Acharya et al., <u>271</u> , No. 41, (Oct. 1996) pp. 25406-411;
2.	AS	J. Mol. Biol., "Basic Local Alignment Search Tool", S.F. Altschul et al., (1990) <u>215</u> , pp. 403-410;
3.	AT	Lett. Nature, "Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor", F. Revah et al., <u>353</u> , (Oct. 1991), pp. 846- ;

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

4.	AU	Nature, "RAGE and Amyloid- β -peptide neurotoxicity in Alzheimer's disease", Shi Du Yan et al., <u>382</u> , (Aug. 1996) pp. 685-691; MAY 29 2001 U.S. TRADE COMMISSION
5.	AV	Nature, "Scavenger receptor-mediated adhesion of microglia to β -amyloid fibrils", J. El Khoury et al., <u>382</u> (Aug. 1996), pp. 716-719;
6.	AW	Nature, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease", <u>349</u> (Feb. 1991), pp. 704-706;
7.	AX	Nature Genetics, "Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β -amyloid precursor protein gene", L. Hendriks et al., <u>1</u> (June 1992), pp. 218-221.
8.	AY	Neurobiology of Aging, "A novel species-specific RNA related to alternatively spliced amyloid precursor protein mRNAs", J.S. Jacobsen et al., <u>12</u> , (1991) pp. 575-583.
9.	AZ	J. Biol. Chem., "The release of Alzheimer's disease β amyloid peptide is reduced by phorbol treatment", J.S. Jacobsen et al., <u>269</u> , No. 11 (March 1994), pp. 8376-8382.
10.	AR2	Mol. Cell. Biol., "Effects of expression of mammalian G α and hybrid mammalian yeast G α proteins on the yeast pheromone response signal transduction pathway", Yoon-Se Kang et al., <u>10</u> , No. 6 (June 1990), pp. 2582-2590.
11.	AS2	Nat. Genetics, "The Alzheimer's A β peptide induces neurodegeneration and apoptotic cell death in transgenic mice", <u>9</u> , (Jan. 1995), pp. 21-30.
12.	AT2	A. Neuropathol., "Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ", H. Lassman et al., <u>89</u> (Springer-Vertaag 1995), pp. 35-41.
13.	AU2	Science, "Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type", <u>243</u> , (June 1990), pp. 1124-1126.
14.	AV2	Neurobiology, "Apoptosis is induced by β -amyloid in cultured central nervous system neurons", D.T. Loo et al., <u>90</u> , (Sept. 1993), pp. 7951-7955.
15.	AW2	Med. Sciences, "Reversible in vitro growth of Alzheimer disease β -amyloid plaques by deposition of labeled amyloid peptide", J.E. Maggio et al., <u>89</u> (June 1992), pp. 5462-5466.
16.	AX2	Nat. Genetics, "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β -amyloid", M. Mullan et al., <u>1</u> (Aug. 1992), pp. 345-347.



OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

17.	AY2	Sci., "A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease", J. Murrell et al., <u>254</u> (Oct. 1991), pp. 97-99.
		MAY 19 2001
18.	AZ2	Lett. Nat., "Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G _o ", I. Nishimoto et al., <u>362</u> (March 1993), pp. 75-79.
		TRADE SHOW
19.	AR3	Nat. Medicine, "Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease", D. Scheuner et al., <u>2</u> No. 8 (Aug. 1996), pp. 864-70.
20.	AS3	Neurosci., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments", D.J. Selkoe, <u>275</u> (Jan. 1997), pp. 630-31.
21.	AT3	J. Neurosci., "Voltage-gated K ⁺ channel β subunits: Expression and distribution of Kv β 1 and Kv β 2 in adult rat brain", K.J. Rhodes et al., <u>16</u> (Aug. 1996), pp. 4846-60.
22.	AU3	Mol. Endo., "Functional interaction of ligands and receptors of the hematopoietic superfamily in yeast", B.A. Ozenberger et al., <u>9</u> No. 10 (1995), pp. 1321-29.
23.	AV3	Exp. Neurology, "Evidence of apoptotic cell death in Alzheimer's disease", G. Smale et al., <u>133</u> (1995), pp. 225-30.
24.	AW3	Sci., "Amyloid β protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus", (Jan. 1987), pp. 880-84.
25.	AX3	Proc. Natl. Acad. Sci., "Detection of conserved segments in proteins: Iterative scanning of sequence databases with alignment blocks", R.L. Tatusov et al., <u>91</u> (Dec. 1994), pp. 12091-95.
26.	AY3	Cell, "The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases", J. Wade Harper et al., <u>75</u> (Nov. 1993), pp. 805-16.
27.	AZ3	Elsevier Sci., "Ultrastructural analysis of β -amyloid-induced apoptosis in cultured hippocampal neurons", J.A. Watt et al., <u>661</u> (1994), pp. 147-156.
28.	AR4	Sci., "G-protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP", T. Yamatsuji et al., <u>272</u> (May 1996), pp. 1349-52.
29.	AS4	Nature, "An intracellular protein that binds amyloid- β peptide and mediates neurotoxicity in Alzheimer's disease", Shi Du Yan et al., <u>389</u> (Oct. 1997), pp. 689-

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

30.	AT4	Science, Lewin, <u>237</u> (1987), p. 1570.
31.	AU4	MAY 10 2001 Biotech Adv., Gellissen et al., <u>10</u> (1992), pp. 179-189.
32.	AV4	Nature, Adams et al., <u>377</u> (1995), pp. 3-174.
33.	AW4	Genbank Accession Number AA306979, Adams et al., 1995.
34.	AX4	Glossary of Genetics and Cytogenetics, Rieger et al., 1976, pp. 17-18.
35.	AY4	Journal of Cell Biology, Burgess et al., <u>111</u> (1990), pp. 2129-2138.
36.	AZ4	Molecular and Cellular Biology, Lazar et al., <u>8</u> (3) (March 1988), pp. 1247-1252.
37.	AR5	"Peptide Hormones," Rüdinger, University Park Press, June 1976, pp. 1-7.
38.	AS5	"Molecular Cloning," Sambrook et al., Second Edition, Cold Spring Harbor Laboratory Press, 1989, pp. 17.1-17.44.
39.	AT5	DATABASE EMBL - EMEST7 'Online! Entry/Acc.no. AI143226, 29 September 1998 (1998-09-29) Strausberg, R., "qb76e01.x1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:1706040 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN; mRNA sequence." XP002135394
40.	AU5	DATABASE EMBL - EMEST1 'Online! Entry/Acc.no. AA628537, 28 October 1997 (1997-10-28) Hillier, L., et al., "af27h04.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032919 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN;" XP002135395
41.	AV5	DATABASE EMBL - EMEST3 'Online! Entry/Acc.no. AA772225, 31 January 31, 1998 (1998-01-31) Strausberg, R., et al., "ai41c01.s1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone 1359552 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN; mRNA" XP002135396
42.	AW5	Proc. Nat'l. Acad. Sci. USA, "Expression, stability, and membrane integration of truncation mutants of bovine rhodopsin," Heymann, J.A.W., et al., <u>94</u> (1997), pp. 4966-4971.

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

43.	AX5	FASEB Journal, "A novel family of apoptosis modulators contain a G protein coupling motif," Kajkowski, E., et al., <u>13</u> (1999), pp. A1434-Abstr. 589.
44.	AY5	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 10 May 1996, XP002081589 HINXTON, GB, AC=W29859. Soares mouse p3NMF 19.5 Mus musculus cDNA clone 348008 5', similar to GTP-BINDING PROTEIN.
45.	AZ5	The Journal of Biological Chemistry, "Arrest of beta-amyloid fibril formation by a peptapeptide ligand," Tjernberg, L.O., et al., <u>271</u> (1996), pp. 8545-8548.
46.	AR6	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 22 July 1998, XP002081601 HINXTON, GB, AC=AI057115. Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone, similar to GTP-binding protein. Spans from nt 3260632; Spans from aa residues 1-101.
 <p align="center">MAY 29 2001</p>		
 <p align="center">PATENT & TRADEMARK OFFICE</p>		
Examin R:		Date Considered:
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPRP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		